201 related articles for article (PubMed ID: 33724151)
1. Development and optimization of TPGS-based stealth liposome of doxorubicin using Box-Behnken design: characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells.
Kurmi BD; Paliwal SR
J Liposome Res; 2022 Jun; 32(2):129-145. PubMed ID: 33724151
[TBL] [Abstract][Full Text] [Related]
2. α-Tocopherol Polyethylene Glycol 1000 Succinate-Based Cationic Liposome for the Intracellular Delivery of Doxorubicin in MDA-MB-231 Triple-Negative Breast Cancer Cell Line.
Sandal P; Patel P; Singh D; Gupta GD; Kurmi BD
Assay Drug Dev Technol; 2023; 21(8):345-356. PubMed ID: 38010987
[No Abstract] [Full Text] [Related]
3. Multifunctional nanotherapeutics for intracellular trafficking of doxorubicin against breast cancer.
Kurmi BD; Patel P; Paliwal R; Kumar P; Paliwal SR
Nanomedicine (Lond); 2023 Aug; 18(19):1261-1279. PubMed ID: 37721134
[TBL] [Abstract][Full Text] [Related]
4. Quality by design-assisted development of D-α-tocopherol polyethylene glycol 1000 succinate-incorporated gefitinib-loaded cationic liposome(s).
Mishra L; Bhowmik S; Singh R; Patel P; Gupta GD; Kurmi BD
Ther Deliv; 2023 Dec; 14(12):745-761. PubMed ID: 38018431
[No Abstract] [Full Text] [Related]
5. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.
Li N; Fu T; Fei W; Han T; Gu X; Hou Y; Liu Y; Yang J
J Pharm Pharmacol; 2019 Aug; 71(8):1243-1254. PubMed ID: 31215039
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E-based micelles enhance the anticancer activity of doxorubicin.
Danhier F; Kouhé TT; Duhem N; Ucakar B; Staub A; Draoui N; Feron O; Préat V
Int J Pharm; 2014 Dec; 476(1-2):9-15. PubMed ID: 25245548
[TBL] [Abstract][Full Text] [Related]
7. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
8. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of Doxorubicin and D-α-Tocopherol Polyethylene Glycol 1000 Succinate by Magnetic Nanoparticles.
Metin E; Mutlu P; Gündüz U
Anticancer Agents Med Chem; 2018; 18(8):1138-1147. PubMed ID: 29532763
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution, in vitro cytotoxicity and biocompatibility of Vitamin E TPGS coated trans resveratrol liposomes.
Vijayakumar MR; Vajanthri KY; Balavigneswaran CK; Mahto SK; Mishra N; Muthu MS; Singh S
Colloids Surf B Biointerfaces; 2016 Sep; 145():479-491. PubMed ID: 27236510
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance.
Li Y; Tan X; Liu X; Liu L; Fang Y; Rao R; Ren Y; Yang X; Liu W
Asian J Pharm Sci; 2020 Sep; 15(5):646-660. PubMed ID: 33193866
[TBL] [Abstract][Full Text] [Related]
12. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
13. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
Yang B
Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
[TBL] [Abstract][Full Text] [Related]
14. Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization,
Rizwanullah M; Perwez A; Mir SR; Alam Rizvi MM; Amin S
Nanotechnology; 2021 Jul; 32(41):. PubMed ID: 34198267
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Farooq MA; Xinyu H; Jabeen A; Ahsan A; Seidu TA; Kutoka PT; Wang B
Colloids Surf B Biointerfaces; 2021 Mar; 199():111523. PubMed ID: 33360624
[TBL] [Abstract][Full Text] [Related]
16. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
17. "TPGS surface modified bilosomes as boosting cytotoxic oral delivery systems of curcumin against doxorubicin resistant MCF-7 breast cancer cells".
Hegazy H; Amin MM; Fayad W; Zakaria MY
Int J Pharm; 2022 May; 619():121717. PubMed ID: 35378174
[TBL] [Abstract][Full Text] [Related]
18. Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
Ong JC; Sun F; Chan E
J Liposome Res; 2011 Dec; 21(4):261-71. PubMed ID: 21226547
[TBL] [Abstract][Full Text] [Related]
19. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
20. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
